ERBB2 and breast cancer: Administration of 99mTc-labeled HER2-targeting affibody ABH2 in an open-label phase I clinical trial (NCT03546478) in HER2-positive breast cancer patients showed a specific binding (overall specificity 60%) of the affibodies to their target molecule without noticeable adverse effects for the patient.